232 related articles for article (PubMed ID: 31041628)
21. A Prognostic Model for Predicting Overall Survival in Patients with Peritoneal Surface Malignancy of an Appendiceal Origin Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Ihemelandu C; Fernandez S; Sugarbaker PH
Ann Surg Oncol; 2017 Aug; 24(8):2266-2272. PubMed ID: 28342015
[TBL] [Abstract][Full Text] [Related]
22. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
Ihemelandu C; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
[TBL] [Abstract][Full Text] [Related]
23. Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?
Kelly KJ; Alsayadnasser M; Vaida F; Veerapong J; Baumgartner JM; Patel S; Ahmad S; Barone R; Lowy AM
Ann Surg Oncol; 2019 May; 26(5):1421-1427. PubMed ID: 30815802
[TBL] [Abstract][Full Text] [Related]
24. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
[TBL] [Abstract][Full Text] [Related]
25. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
26. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA;
Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
[TBL] [Abstract][Full Text] [Related]
27. Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival.
Wagner PL; Austin F; Maduekwe U; Mavanur A; Ramalingam L; Jones HL; Holtzman MP; Ahrendt SA; Zureikat AH; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2013 Apr; 20(4):1056-62. PubMed ID: 23456385
[TBL] [Abstract][Full Text] [Related]
28. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
29. Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study.
Madsen AH; Ladekarl M; Villadsen GE; Grønbæk H; Sørensen MM; Stribolt K; Verwaal VJ; Iversen LH
Ann Surg Oncol; 2018 Feb; 25(2):422-430. PubMed ID: 29214450
[TBL] [Abstract][Full Text] [Related]
30. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.
Cornali T; Sammartino P; Kopanakis N; Christopoulou A; Framarino Dei Malatesta M; Efstathiou E; Spagnoli A; Ciardi A; Biacchi D; Spiliotis J
Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600
[TBL] [Abstract][Full Text] [Related]
31. Long-term Survival and Propensity Score Matched Outcomes of Bilateral
Singh B; Singh G; Pourgholami M; Alzahrani N; Morris DL
Anticancer Res; 2018 Oct; 38(10):5917-5921. PubMed ID: 30275219
[TBL] [Abstract][Full Text] [Related]
32. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
33. ASO Author Reflections: The Diminishing Role of Adjuvant HIPEC.
Enomoto LM; Shen P
Ann Surg Oncol; 2020 Jan; 27(1):115-116. PubMed ID: 31720936
[No Abstract] [Full Text] [Related]
34. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Milovanov V; Sardi A; Studeman K; Nieroda C; Sittig M; Gushchin V
Ann Surg Oncol; 2016 Jun; 23(6):1928-33. PubMed ID: 26714951
[TBL] [Abstract][Full Text] [Related]
35. Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC.
Schneider MA; Eshmuminov D; Lehmann K
Ann Surg Oncol; 2017 Aug; 24(8):2224-2232. PubMed ID: 28265776
[TBL] [Abstract][Full Text] [Related]
36. Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries.
Mogal HD; Levine EA; Russell G; Shen P; Stewart JH; Votanopoulos KI
Ann Surg Oncol; 2016 Feb; 23(2):534-8. PubMed ID: 26289808
[TBL] [Abstract][Full Text] [Related]
37. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Ahmed S; Levine EA; Randle RW; Swett KR; Shen P; Stewart JH; Votanopoulos KI
Ann Surg Oncol; 2014 Dec; 21(13):4226-31. PubMed ID: 25034815
[TBL] [Abstract][Full Text] [Related]
38. Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative.
Levinsky NC; Morris MC; Wima K; Sussman JJ; Ahmad SA; Cloyd JM; Kimbrough C; Fournier K; Lee A; Dineen S; Dessureault S; Veerapong J; Baumgartner JM; Clarke C; Zaidi MY; Staley CA; Maithel SK; Leiting J; Grotz T; Lambert L; Hendrix RJ; Ronnekleiv-Kelly S; Pokrzywa C; Raoof M; Eng OS; Johnston FM; Greer J; Patel SH
J Gastrointest Surg; 2020 Jan; 24(1):155-164. PubMed ID: 31428960
[TBL] [Abstract][Full Text] [Related]
39. Does obesity affect outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for disseminated mucinous appendiceal neoplasms?
Polanco PM; Sanchez AI; Ramalingam L; Jones H; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2014 Nov; 21(12):3963-9. PubMed ID: 24916747
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P
Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
